Group-A (N=62) Group-P (N=49) Group-A+P (N=29) Total (N=140)
P
Immunomodulation-related treatments
Proglobulin, n (%) 10 (16.1%) 11 (22.4%) 12 (41.4%) 33 (23.6%) 0.030
Monoclonal antibodies, n (%) 6 (9.7%) 1 (2%) 1 (3.4%) 8 (5.7%) 0.179
Intravenous hormone use, n (%) 23 (37.1%) 31 (63.3%) 22 (75.9%) 76 (54.3%) 0.001
Immunosuppressant adjustment
CNI reduction, n (%) 28 (45.2%) 48 (98.0%) 26 (96.3%) 102 (73.9%) 0.000
MMF reduction, n (%) 56 (90.3%) 46 (93.9%) 28 (96.5%) 130 (92.9%) 0.509
CNI deactivation, n (%) 16 (25.8%) 47 (95.9%) 27 (93.1%) 90 (64.3%) 0.000
MMF deactivation, n (%) 53 (85.5%) 38 (77.5%) 27 (93.1%) 118 (84.3%) 0.178
CNI and MMF are both deactivated, n (%) 18 (29.0%) 36 (73.5%) 24 (82.8%) 78 (55.7%) 0.000
Number of days off immunosuppressive drugs,median (IQR) 7.0 (6.0,9.5) 7.0 (6.0,9.5) 8.5 (7.0,14.0) 7.0 (6.0,10.0) 0.071